Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00313729 · FLOW

Participant flow

Temozolomide in Treating Patients With Low-Grade Glioma · Source last updated 2019-02-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Oral temozolomide at 200mg/m2 per day x5 days every 28 days for up to 12 cycles
    id
    FG000
    title
    Single Arm Study of Temozolomide for LGG Patients
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        120
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        120
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Oral temozolomide at 200mg/m2 per day x5 days every 28 days for up to 12 cycles
    id
    FG000
    title
    Single Arm Study of Temozolomide for LGG Patients
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        120
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        120
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice